Biotech Values

[poorgradstudent]

Just thinking that, in general, one would expect a biotech with a smaller market cap to likely have less negotiating leverage compared to a biotech with a much higher market cap and so it's more impressive when a smaller biotech is able to negotiate for impressive milestone payments.

Yeah, I understand that angle. But then we can also ask why THLD has a comparatively lower market cap than companies that received large payments prior to phase III.

I think, as with most parts of biotech - pharma collaborations, these things are hard to read into.

Data talk, regardless of the dollars thrown around